Company Filing History:
Years Active: 2021-2025
Title: Alan Silcock: Pioneer in Cannabinoid Formulations
Introduction
Alan Silcock is an innovative inventor based in Cambridge, GB, known for his significant contributions to the field of cannabinoid formulations. With a focus on pH dependent release technology, Silcock has developed novel microparticle formulations that aim to enhance the therapeutic delivery of cannabinoids.
Latest Patents
Silcock holds a patent for his work titled "pH dependent release coated microparticle cannabinoid formulations." This patent reveals a microparticulate system that comprises one or more cannabinoids along with a pH dependent release polymer. Notably, the formulation can contain cannabinoids in amounts ranging from 10% w/w to about 50% w/w, and the release polymer can vary from about 5% w/w to about 85% w/w. This innovative approach enhances the controlled release of cannabinoids, making it a significant advancement in pharmaceutical formulations.
Career Highlights
Alan Silcock is associated with GW Research Limited, a pioneer in cannabinoid research and product development. His career is marked by a commitment to advancing the therapeutic potential of cannabinoids through rigorous research and development. His work holds promise for improving patient outcomes in various medical applications.
Collaborations
In his journey, Silcock collaborates closely with Jitinder Wilkhu, leveraging their shared expertise to push the boundaries of cannabinoid innovation. Their partnership has been instrumental in refining formulation techniques and expanding the possibilities of cannabinoid applications in healthcare.
Conclusion
Alan Silcock's pioneering work in cannabinoid formulations underscores the potential of innovative therapies in modern medicine. With his patented microparticle technology, Silcock stands at the forefront of cannabinoid research, contributing valuable insights and advancements that could reshape treatment methodologies for various conditions.